Co-Diagnostics (CODX) Earnings Analysis
Co-Diagnostics (CODX) next reports earnings on 2026-08-14, consensus EPS -3 USD. Last quarter (2026-05-14) it missed with EPS -4.06 USD vs -3.75 USD est (-8.3%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -0.07.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CODX next report earnings?
| Next earnings date | 2026-08-14 |
|---|---|
| Consensus EPS estimate | -3 USD |
| Revenue estimate | 0.00B |
CODX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | -4.06 USD | -3.75 USD | -8.3% | Miss |
| 2026-03-31 | -16.35 USD | -3.6 USD | -354.2% | Miss |
| 2025-11-13 | -4.8 USD | -5.71 USD | +15.9% | Beat |
| 2025-08-14 | -0.23 USD | -0.25 USD | +8% | Beat |
| 2025-05-08 | -0.24 USD | -0.33 USD | +27.3% | Beat |
| 2024-11-07 | -0.32 USD | -0.33 USD | +3% | Beat |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
CODX valuation and analyst view
| Trailing P/E | -0.07 |
|---|---|
| Trailing EPS | -21.52352 USD |
| Price / book | 0.32 |
| Dividend yield | 0.00% |
| Market cap | 0.00B |
| Analyst consensus | Hold (2 buy / 3 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Co-Diagnostics (CODX)'s next earnings date?
Co-Diagnostics is next scheduled to report on 2026-08-14, with a consensus EPS estimate of -3 USD and revenue estimate of 0.00B.
Did CODX beat earnings last quarter?
In its 2026-05-14 report, CODX posted EPS of -4.06 USD versus a -3.75 USD estimate — a miss of 8.3%.
What is CODX's earnings track record?
Over the last 6 reported quarters with consensus data, CODX beat estimates 4 times (67%).
What is CODX's current P/E ratio and EPS?
CODX trades at a trailing P/E of -0.07 on trailing EPS of -21.523524566957505 USD.
What do analysts rate CODX?
Analyst consensus is "Hold" across 5 ratings (0 strong buy, 2 buy, 3 hold, 0 sell, 0 strong sell).